Mefenamic Acid Tillomed Laboratories (Mefenamic Acid)

Mefenamic acid works by non‑selectively inhibiting cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which reduces the synthesis of prostaglandins. Lower prostaglandin levels lead to decreased inflammation, pain signaling, and fever, providing symptomatic relief.

The dosage of mefenamic acid is determined by the prescribing clinician based on the patient’s condition, age, weight, and response to therapy. The prescriber will select an appropriate regimen that balances efficacy with safety.

Safety data for mefenamic acid in pregnancy and lactation are limited. It should be used only when clearly needed and after a thorough risk‑benefit assessment by a healthcare professional. Breastfeeding mothers should consult their physician before use.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Mefenamic acid is a non‑selective NSAID similar to ibuprofen and naproxen but often chosen for its efficacy in dysmenorrhea. Compared with COX‑2 selective agents, it has a broader COX inhibition profile, which may increase gastrointestinal risk but can provide stronger anti‑inflammatory effects in certain patients.

Store the product at ambient temperature, preferably below 25 °C, in its original container. Keep it away from moisture, direct sunlight, and heat sources. Ensure the packaging remains intact until the point of use to maintain product stability.

Mefenamic Acid Tillomed is taken orally, usually with a full glass of water. It can be taken with food or after meals to lessen gastrointestinal irritation. Patients should follow the dosing schedule prescribed by their healthcare provider.

Serious risks include gastrointestinal ulceration or bleeding, renal impairment, severe skin reactions such as Stevens‑Johnson syndrome, hepatic dysfunction, and rare blood disorders. Patients should seek immediate medical attention if they experience signs of bleeding, severe rash, or unexplained fatigue.

Mefenamic acid should be avoided in individuals with known hypersensitivity to the drug or other NSAIDs, active peptic ulcer disease, severe renal or hepatic impairment, uncontrolled hypertension, and in patients who are in the third trimester of pregnancy. A healthcare professional should evaluate suitability before prescribing.